Compare JACK & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | MDWD |
|---|---|---|
| Founded | 1951 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Restaurants | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.1M | 202.6M |
| IPO Year | 1994 | 2013 |
| Metric | JACK | MDWD |
|---|---|---|
| Price | $14.25 | $13.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 6 |
| Target Price | $19.75 | ★ $29.67 |
| AVG Volume (30 Days) | ★ 420.0K | 146.3K |
| Earning Date | 12-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $1,465,314,000.00 | N/A |
| Revenue This Year | N/A | $32.97 |
| Revenue Next Year | $0.91 | $39.75 |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.92 | $11.80 |
| 52 Week High | $23.86 | $19.70 |
| Indicator | JACK | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 54.17 | 50.06 |
| Support Level | $13.24 | $12.05 |
| Resistance Level | $18.15 | $14.52 |
| Average True Range (ATR) | 0.77 | 0.70 |
| MACD | 0.12 | -0.02 |
| Stochastic Oscillator | 62.95 | 37.79 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.